Genetic and epigenetic markers in colorectal cancer screening: recent advances

References

• Stewart BW and Wild CP.  World cancer report 2014. World Health Organization, IARC Press, Lyon, France; 2014.
   Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Weinberg DS. Biomarkers in colorectal cancer screening. J Natl Compr Cancer Netw JNCCN. 2016;14:1033–1040.
   PubMed Web of Science ®Google Scholar
• Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–2072.
   PubMed Web of Science ®Google Scholar
• Hesson LB, Ng B, Zarzour P, et al. Integrated genetic, epigenetic, and transcriptional profiling identifies molecular pathways in the development of laterally spreading tumors. Mol Cancer Res. 2016;14:1217–1228.
   PubMed Web of Science ®Google Scholar
• Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27:9–14.
   PubMedGoogle Scholar
• Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015;6:660–667.
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn JMD. 2007;9:305–314.
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–793.
   PubMed Web of Science ®Google Scholar
• Fu L, Chen L, Yang J, et al. HIF-1 -induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis. 2012;33:1664–1673.
   PubMed Web of Science ®Google Scholar
• Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337.
   PubMed Web of Science ®Google Scholar
• Rodríguez–Soler M, Pérez–Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected Lynch syndrome without germline mutation. Gastroenterology. 2013;144:926–932.e1.
   PubMed Web of Science ®Google Scholar
• Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers. 2013;5:676–713.
   PubMedGoogle Scholar
• Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149:1177–1190.e3.
   PubMed Web of Science ®Google Scholar
• Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep. 2015;gov046.
   Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–1356.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091–2096.
   PubMed Web of Science ®Google Scholar
• Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer. 2001;85:692–696.
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–762.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:13–21.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:1626–1634.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26:2–2.
   Web of Science ®Google Scholar
• Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589–600.
   PubMed Web of Science ®Google Scholar
• Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis: figure 1. Biochem Soc Trans. 2005;33:672–675.
   PubMed Web of Science ®Google Scholar
• Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer. 2003;2:41.
   PubMedGoogle Scholar
• Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14:16365–16385.
   PubMed Web of Science ®Google Scholar
• Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer. 2005;5:199–209.
   PubMed Web of Science ®Google Scholar
• Suceveanu AI, Suceveanu A, Voinea F, et al. Introduction of cytogenetic tests in colorectal cancer screening. J Gastrointest Liver Dis JGLD. 2009;18:33–38.
   PubMed Web of Science ®Google Scholar
• Mak T, Lalloo F, Evans DGR, et al. Molecular stool screening for colorectal cancer. Br J Surg. 2004;91:790–800.
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170.
   PubMed Web of Science ®Google Scholar
• Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044–2058.
   PubMed Web of Science ®Google Scholar
• Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:466–474.
   PubMed Web of Science ®Google Scholar
• Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1254–1261.
   PubMed Web of Science ®Google Scholar
• Khan SA, Zeng Z, Shia J, et al. EGFR gene amplification and KRAS mutation predict response to combination targeted therapy in metastatic colorectal cancer. Pathol Oncol Res. 2017;23:673-677.
   PubMed Web of Science ®Google Scholar
• Linardou H, Briasoulis E, Dahabreh IJ, et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev. 2011;37:221–233.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int. 2015;2015:1–14.
   Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–1606.
   PubMed Web of Science ®Google Scholar
• Kim A, Lee J-E, Lee -S-S, et al. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer. 2013;133:984–996.
   PubMed Web of Science ®Google Scholar
• Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18:2257–2268.
   PubMed Web of Science ®Google Scholar
• Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 2017;87:8–19.
   PubMed Web of Science ®Google Scholar
• Bronte G, Silvestris N, Castiglia M, et al. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget. 2015;6:24780–24796.
   PubMed Web of Science ®Google Scholar
• Read ML, Seed RI, Modasia B, et al. The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer: overexpression of PBF In colorectal cancer. Mol Carcinog. 2016;55:15–26.
   PubMed Web of Science ®Google Scholar
• Graham DM, Coyle VM, Kennedy RD, et al. Molecular subtypes and personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2016;12:141–150.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1814–1821.
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–257.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang B, Chen X, et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer. 2014;110:946–957.
   PubMed Web of Science ®Google Scholar
• Eklöf V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer. 2013;108:2153–2163.
   PubMed Web of Science ®Google Scholar
• Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–1270.
   PubMed Web of Science ®Google Scholar
• Leggett BA. AACR Special Conference: Colorectal Cancer: From Initiation to Outcomes; September 17-20, 2016; Tampa, FL. Abstract IA05: the serrated pathway of colorectal tumorigenesis. Cancer Res. 2017;77:IA05–IA05.
   Web of Science ®Google Scholar
• Day F, Muranyi A, Singh S, et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol. 2015;10:99–109.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
   PubMed Web of Science ®Google Scholar
• Samuels Y. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554–554.
   PubMed Web of Science ®Google Scholar
• Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64:1419–1425.
   PubMed Web of Science ®Google Scholar
• Paleari L, Puntoni M, Clavarezza M, et al. PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies. Clin Oncol. 2016;28:317–326.
   PubMed Web of Science ®Google Scholar
• Kudryavtseva AV, Lipatova AV, Zaretsky AR, et al. Important molecular genetic markers of colorectal cancer. Oncotarget. 2016;7:53959–53983.
   PubMed Web of Science ®Google Scholar
• Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumor Biol. 2010;31:623–631.
   PubMed Web of Science ®Google Scholar
• Uddin S, Ahmed M, Hussain A, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010;126:382–394.
   PubMed Web of Science ®Google Scholar
• Huang L, Liu Z, Deng D, et al. Systematic review/meta-analysis anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci. 2014;1:1–9.
   Web of Science ®Google Scholar
• Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. Ashktorab H, editor. Plos ONE. 2013;8:e65479.
   PubMed Web of Science ®Google Scholar
• Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002;89:845–860.
   PubMed Web of Science ®Google Scholar
• De Bruijn MT, Raats DAE, Hoogwater FJH, et al. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer. 2010;102:1254–1264.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1386–1422.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 2009;27:4591–4598.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–1206.
   PubMed Web of Science ®Google Scholar
• Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer Oxf Engl. 1990;2005(41):2060–2070.
   Google Scholar
• Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.
   PubMed Web of Science ®Google Scholar
• Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91:1295–1303.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004;20:199–206.
   PubMed Web of Science ®Google Scholar
• Salahshor S, Koelble K, Rubio C, et al. Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest. 2001;81:535–541.
   PubMed Web of Science ®Google Scholar
• Palles C, Cazier J-B, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2012;45:136–144.
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015;149:1204–1225.e12.
   PubMed Web of Science ®Google Scholar
• Ashktorab H, Brim H. DNA methylation and colorectal cancer. Curr Colorectal Cancer Rep. 2014;10:425–430.
   PubMedGoogle Scholar
• Hashimoto Y, Zumwalt TJ, Goel A. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Epigenomics. 2016;8:685–703.
   PubMed Web of Science ®Google Scholar
• Zamani M, Hosseini SV, Mokarram P. Epigenetic biomarkers in colorectal cancer: premises and prospects. Biomarkers. 2016;1–10.
   PubMedGoogle Scholar
• Melotte V, Lentjes MHFM, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009;101:916–927.
   PubMed Web of Science ®Google Scholar
• Nilsson T. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol. 2012;42(1):127–133.
   PubMed Web of Science ®Google Scholar
• Hellebrekers DMEI, Lentjes MHFM, Van Den Bosch SM, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009;15:3990.
   PubMed Web of Science ®Google Scholar
• Wallner M, Herbst A, Behrens A, et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:7347–7352.
   PubMed Web of Science ®Google Scholar
• Rawson JB, Manno M, Mrkonjic M, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. 2011;32:741–747.
   PubMed Web of Science ®Google Scholar
• Takeda M, Nagasaka T, Dong-Sheng S, et al. Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama. 2011;65:169–177.
   PubMed Web of Science ®Google Scholar
• Abdelmaksoud-Dammak R, Miladi-Abdennadher I, Saadallah-Kallel A, et al. Downregulation of WIF-1 and Wnt5a in patients with colorectal carcinoma: clinical significance. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:7975–7982.
   Google Scholar
• Amiot A, Mansour H, Baumgaertner I, et al. The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening. Lo AWI, editor. Plos ONE. 2014;9:e99233.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Guo Q, et al. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis Markers. 2015;2015:1–6.
   Google Scholar
• Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133.
   PubMed Web of Science ®Google Scholar
• Wei J, Li G, Zhang J, et al. Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer. Oncotarget. 2016;7:62547–62558.
   PubMed Web of Science ®Google Scholar
• Ebert MPA, Model F, Mooney S, et al. Aristaless-like Homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology. 2006;131:1418–1430.
   PubMed Web of Science ®Google Scholar
• Salehi R, Atapour N, Vatandoust N, et al. Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer. Adv Biomed Res. 2015;4:252.
   PubMedGoogle Scholar
• Xiao W, Zhao H, Dong W, et al. Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer. Oncol Lett. 2015;9:1383–1387.
   PubMed Web of Science ®Google Scholar
• Azuara D, Rodriguez-Moranta F, De Oca J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer. 2010;9:168–176.
   PubMed Web of Science ®Google Scholar
• Zhang X. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21:2629.
   PubMed Web of Science ®Google Scholar
• Cleven AHG, Derks S, Draht MXG, et al. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. Clin Cancer Res. 2014;20:3261–3271.
   PubMed Web of Science ®Google Scholar
• Da Silva T, Vidigal V, Felipe A, et al. P-192 * DNA methylation profile of APC and DKK2 genes as biomarkers in colorectal cancer patients. Ann Oncol. 2015;26:iv55–iv56.
   Web of Science ®Google Scholar
• Magnani G, Furlan D, Sahnane N, et al. Molecular features and methylation status in early onset (≤40 Years) colorectal cancer: a population based, case-control study. Gastroenterol Res Pract. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Tsai M-H, Chen W-C, Yu S-L, et al. DNA hypermethylation of SHISA3 in colorectal cancer: an independent predictor of poor prognosis. Ann Surg Oncol. 2015;22:1481–1489.
   PubMed Web of Science ®Google Scholar
• Szmida E, Karpiński P, Leszczynski P, et al. Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer. J Appl Genet. 2015;56:185–192.
   PubMed Web of Science ®Google Scholar
• Matthaios D, Balgkouranidou I, Karayiannakis A, et al. Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol Lett. 2016;12:748–756.
   PubMed Web of Science ®Google Scholar
• Tan S-H, Ida H, Lau Q-C, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18:1225–1230.
   PubMed Web of Science ®Google Scholar
• Ahmed D, Danielsen SA, Aagesen TH, et al. A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clin Trans Gastroenterol. 2012;3:e27.
   PubMed Web of Science ®Google Scholar
• Pedersen SK, Baker RT, McEvoy A, et al. A two-gene blood test for methylated DNA sensitive for colorectal cancer. Corvalán AH, Editor. PLOS ONE. 2015;10:e0125041.
   PubMed Web of Science ®Google Scholar
• Juo YY, Johnston FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014;25:2314–2327.
   PubMed Web of Science ®Google Scholar
• Chen W-D, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97:1124–1132.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31:141–149.
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. JNCI J Natl Cancer Inst. 2009;101:1244–1258.
   Web of Science ®Google Scholar
• Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009;69:4691–4699.
   PubMed Web of Science ®Google Scholar
• Ohata Y. Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M. Mol Hum Reprod. 2001;7:665–670.
   PubMed Web of Science ®Google Scholar
• Kim MS, Louwagie J, Carvalho B, et al. Promoter DNA methylation of oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer. Weitzman J, editor. Plos ONE. 2009;4:e6555.
   PubMed Web of Science ®Google Scholar
• Baek YH, Chang E, Kim YJ, et al. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 2009;52:1452–1459.
   PubMed Web of Science ®Google Scholar
• Levin TR, Corley DA, Jensen CD, et al. Genetic biomarker prevalence is similar in fecal immunochemical test positive and negative colorectal cancer tissue. Dig Dis Sci. 2017;62:678–688.
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Weljie AM, Kopciuk KA, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer. 2016;115:848–857.
   PubMed Web of Science ®Google Scholar
• Herzog M, Eccleston ME, Pamart D, et al. A novel epigenetic immunoassay approach to profiling circulating nucleosomes for CRC detection. Ann Oncol. 2016;27:LBA23_PR-LBA23_PR.
   Web of Science ®Google Scholar
• Villar-Vázquez R, Padilla G, Fernández-Aceñero MJ, et al. Development of a novel multiplex beads-based assay for autoantibody detection for colorectal cancer diagnosis. Proteomics. 2016;16:1280–1290.
   PubMed Web of Science ®Google Scholar
• Cosgrove LJ, Surinya K, Fung KY, et al. Abstract 4920: evaluation of a diagnostic blood test for colorectal cancer screening and as a triage tool to stratify patients for colonoscopy. Cancer Res. 2016;76:4920–4920.
   Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;371:187–188.
   PubMed Web of Science ®Google Scholar
• Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.
   PubMed Web of Science ®Google Scholar
• Ned RM, Melillo S, Marrone M. Fecal DNA testing for colorectal cancer screening: the ColoSureTM test. Plos Curr. 2011;3:RRN1220.
   PubMedGoogle Scholar
• Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010;126:1177–1186.
   PubMed Web of Science ®Google Scholar
• Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 2002;346:311–320.
   PubMed Web of Science ®Google Scholar
• Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet Lond Engl. 2002;359:403–404.
   PubMed Web of Science ®Google Scholar
• Puig P, Urgell E, Capellá G, et al. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer. 2000;85:73–77.
   PubMed Web of Science ®Google Scholar
• Malapelle U, Pisapia P, Sgariglia R, et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol. 2016;69:767–771.
   PubMed Web of Science ®Google Scholar
• Gao J, Wu H, Wang L, et al. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR. BMJ Open. 2016;6:e009532.
   PubMed Web of Science ®Google Scholar
• Han S-W, Kim H-P, Shin J-Y, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. Shomron N, editor. Plos ONE. 2013;8:e64271.
   PubMed Web of Science ®Google Scholar
• Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857–865.
   PubMed Web of Science ®Google Scholar
• Al-Tassan NA, Whiffin N, Hosking FJ, et al. A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Sci Rep. 2015;5:10442.
   PubMed Web of Science ®Google Scholar
• Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397–411.
   PubMed Web of Science ®Google Scholar
• Rescigno T, Micolucci L, Tecce M, et al. Bioactive nutrients and nutrigenomics in age-related diseases. Molecules. 2017;22:105.
   Web of Science ®Google Scholar
• Mima K, Nishihara R, Yang J, et al. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:3841–3848.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nishihara R, VanderWeele TJ, et al. Review Article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27:602–611.
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘immunoscore’ in the classification of malignant tumors. J Path. 2014;232(2):199–209.
   PubMed Web of Science ®Google Scholar
• Ng J, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci. 2015;16:2472–2496.
   PubMed Web of Science ®Google Scholar
• Aghagolzadeh P, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 2016;22:5678.
   PubMed Web of Science ®Google Scholar
• Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30:830–833.
   PubMed Web of Science ®Google Scholar
• Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414–423.
   PubMed Web of Science ®Google Scholar
• Liang G, Salem CE, Yu MC, et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics. 1998;53:260–268.
   PubMed Web of Science ®Google Scholar
• Alonso S, González B, Ruiz-Larroya T, et al. Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer. Clin Epigenetics. 2015;7:124.
   PubMed Web of Science ®Google Scholar
• Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000;97(2):710–715.
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29:181–206.
   PubMed Web of Science ®Google Scholar
• Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:686–700.
   PubMed Web of Science ®Google Scholar
• Hur K, Cejas P, Feliu J, et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 2014;63:635–646.
   PubMed Web of Science ®Google Scholar
• Nagai Y, Sunami E, Yamamoto Y, et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget. 2017;8:11906.
   PubMed Web of Science ®Google Scholar
• Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch Int J Pathol. 2011;458:313–322.
   PubMed Web of Science ®Google Scholar
• Ashktorab H, Belgrave K, Hosseinkhah F, et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci. 2009;54:2109–2117.
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400.
   PubMed Web of Science ®Google Scholar
• Stypula-Cyrus Y, Damania D, Kunte DP, et al. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. Gaetano C, Editor. Plos ONE. 2013;8:e64600.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Kondo T, Ma D, et al. Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum Pathol. 2012;43:834–842.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Hieda M, Nishioka Y, et al. Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci. 2013;104:889–895.
   PubMed Web of Science ®Google Scholar
• Muhammad S. MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives. World J Gastroenterol. 2014;20:17011.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Zeitels LR, Acharya A, Shi G, et al. Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis. Genes Dev. 2014;28:2585–2590.
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 2008;299:425–436.
   PubMed Web of Science ®Google Scholar
• Nagel R, Le Sage C, Diosdado B, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68:5795–5802.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang P, Wang F, et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat Commun. 2012;3:1291.
   PubMed Web of Science ®Google Scholar
• Tsuchida A, Ohno S, Wu W, et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci. 2011;102:2264–2271.
   PubMed Web of Science ®Google Scholar
• Sun Z, Meng C, Wang S, et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer. 2014;14:616.
   PubMed Web of Science ®Google Scholar
• Yamada N, Tsujimura N, Kumazaki M, et al. Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. Biochim Biophys Acta. 2014;1839:1256–1272.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang M, Huang Y, et al. MicroRNA-320b promotes colorectal cancer proliferation and invasion by competing with its homologous microRNA-320a. Cancer Lett. 2015;356:669–675.
   PubMed Web of Science ®Google Scholar
• Neerincx M, Sie DLS, van de Wiel MA, et al. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis. 2015;4:e170.
   PubMed Web of Science ®Google Scholar
• Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;(3):CD005390.
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today. 2012;42:1037–1045.
   PubMed Web of Science ®Google Scholar
• Zhang J-X, Song W, Chen Z-H, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14:1295–1306.
   PubMed Web of Science ®Google Scholar
• Nosho K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis. 2014;35:776–783.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Lin Y-M, Chung H-C, et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 2012;72:3631.
   PubMed Web of Science ®Google Scholar
• Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 2010;285:35293–35302.
   PubMed Web of Science ®Google Scholar
• Hwang W-L, Jiang J-K, Yang S-H, et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat Cell Biol. 2014;16:268–280.
   PubMed Web of Science ®Google Scholar
• Sundaram P, Hultine S, Smith LM, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res. 2011;71:7490–7501.
   PubMed Web of Science ®Google Scholar
• Vickers MM, Bar J, Gorn-Hondermann I, et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis. 2012;29:123–132.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Hur K, Tanaka K, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259:735–743.
   PubMed Web of Science ®Google Scholar
• Chai J, Dong W, Xie C, et al. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD: chemoresistance of colon cancer cells. IUBMB Life. 2015;67:191–201.
   PubMed Web of Science ®Google Scholar
• Stiegelbauer V, Perakis S, Deutsch A, et al. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol WJG. 2014;20:11727–11735.
   PubMed Web of Science ®Google Scholar
• Boni V, Zarate R, Villa JC, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J. 2011;11:429–436.
   PubMed Web of Science ®Google Scholar
• Mekenkamp LJM, Tol J, Dijkstra JR, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 2012;12:292.
   PubMed Web of Science ®Google Scholar
• Caramés C, Cristóbal I, Moreno V, et al. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 2015;30:899–906.
   PubMed Web of Science ®Google Scholar
• Simmer F, Venderbosch S, Dijkstra JR, et al. MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget. 2015;6:22996–23007.
   PubMed Web of Science ®Google Scholar
• Perez-Carbonell L, Sinicrope FA, Alberts SR, et al. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 2015;113:83–90.
   PubMed Web of Science ®Google Scholar
• Della Vittoria Scarpati G, Falcetta F, Carlomagno C, et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1113–1119.
   PubMed Web of Science ®Google Scholar
• Svoboda M, Sana J, Fabian P, et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol Lond Engl. 2012;7:195–195.
   PubMed Web of Science ®Google Scholar
• Boisen MK, Dehlendorff C, Linnemann D, et al. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line capecitabine and oxaliplatin with or without bevacizumab. Ray RB, editor. Plos ONE. 2014;9:e109430.
   PubMed Web of Science ®Google Scholar
• Mosakhani N, Sarhadi VK, Borze I, et al. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer. 2012;51:1–9.
   PubMed Web of Science ®Google Scholar
• Igarashi H, Kurihara H, Mitsuhashi K, et al. Association of microRNA-31-5p with clinical efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer. Ann Surg Oncol. 2015;22:2640–2648.
   PubMed Web of Science ®Google Scholar
• Ng EKO, Chong WWS, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375–1381.
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–126.
   PubMed Web of Science ®Google Scholar
• Pu X, Huang G, Guo H, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression: plasma miR-221 predict colorectal cancer. J Gastroenterol Hepatol. 2010;25:1674–1680.
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256:544–551.
   PubMed Web of Science ®Google Scholar
• Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. Goel A, editor. Plos ONE. 2012;7:e44398.
   PubMed Web of Science ®Google Scholar
• Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila Pa). 2010;3:1435–1442.
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Goel A. An update on microRNAs as colorectal cancer biomarkers: where are we and what’s next? Expert Rev Mol Diagn. 2014;14:999–1021.
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46:1391–1402.
   PubMed Web of Science ®Google Scholar
• Wu CW, Ng SSM, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61:739–745.
   PubMed Web of Science ®Google Scholar
• Maierthaler M, Benner A, Hoffmeister M, et al. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer: plasma miR-122 and miR-200 family in CRC. Int J Cancer. 2017;140:176–187.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Imaoka H, Fujikawa H, et al. Abstract 968: circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Cancer Res. 2016;76:968–968.
   Web of Science ®Google Scholar
• Hong Z, Feng Z, Sai Z, et al. PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer in vitro. BMB Rep. 2014;47:500–505.
   PubMed Web of Science ®Google Scholar
• Chang P-Y, Chen -C-C, Chang Y-S, et al. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget. 2016;7:10663.
   PubMed Web of Science ®Google Scholar
• Wu CW, Ng SC, Dong Y, et al. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res. 2014;20:2994–3002.
   PubMed Web of Science ®Google Scholar
• Shi S-Q, Ke -J-J, Wu W-Q, et al. Serum miRNA-203 expression is associated with chemo-response to standard FOLFOX treatment of patients with colorectal cancer. Int J Clin Exp Pathol. 2017;10:105–116.
   Web of Science ®Google Scholar
• Shan B, Chen P, Li S, et al. Decreased expression of microRNA-192 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2017;10:595–602.
   Web of Science ®Google Scholar
• Yau TO, Wu CW, Tang C-M, et al. microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget. 2016;7:1559.
   PubMed Web of Science ®Google Scholar
• Basati G, Razavi AE, Pakzad I, et al. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumor Biol. 2016;37:1781–1788.
   PubMed Web of Science ®Google Scholar
• Lv Z, Fan Y, Chen H, et al. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumor Biol. 2015;36:1619–1625.
   PubMed Web of Science ®Google Scholar
• Caritg O, Navarro A, Moreno I, et al. Identifying high-risk stage II colon cancer patients: a three-microRNA-based score as a prognostic biomarker. Clin Colorectal Cancer. 2016;15:e175–82.
   PubMed Web of Science ®Google Scholar
• Vychytilova-Faltejskova P, Radova L, Sachlova M, et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis. 2016;37:941–950.
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Roberts H, Eichenberger MR, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013;258:400–408.
   PubMed Web of Science ®Google Scholar
• Wang J, Huang S, Zhao M, et al. Identification of a circulating microRNA signature for colorectal cancer detection. Mari B, editor. Plos ONE. 2014;9:e87451.
   PubMed Web of Science ®Google Scholar
• Giráldez MD, Lozano JJ, Ramírez G, et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2013;11:681–688.e3.
   PubMed Web of Science ®Google Scholar
• Li C, Wang X, Casal I, et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med. 2016;20:1420–1426.
   PubMed Web of Science ®Google Scholar
• Song YF, Xu ZB, Zhu XJ, et al. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer. Clin Transl Oncol. 2017;19:519–524.
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–233.
   PubMed Web of Science ®Google Scholar
• Uppara M, Adaba F, Askari A, et al. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer. World J Surg Oncol. 2015;13:48.
   PubMed Web of Science ®Google Scholar
• Wang H-P, Wang -Y-Y, Pan J, et al. Evaluation of specific fecal protein biochips for the diagnosis of colorectal cancer. World J Gastroenterol WJG. 2014;20:1332–1339.
   PubMed Web of Science ®Google Scholar
• Blume JE, Wilhelmsen M, Benz RW, et al. Discovery and validation of plasma-protein biomarker panels for the detection of colorectal cancer and advanced adenoma in a Danish collection of samples from patients referred for diagnostic colonoscopy. J Appl Lab Med AACC Publ. 2016;1:6.
   Google Scholar
• Fernández-Marcelo T, Sánchez-Pernaute A, Pascua I, et al. Clinical relevance of telomere status and telomerase activity in colorectal cancer. Plos One. 2016;11:e0149626.
   PubMed Web of Science ®Google Scholar
• Jia H, Wang Z. Telomere length as a prognostic factor for overall survival in colorectal cancer patients. Cell Physiol Biochem. 2016;38:122–128.
   PubMed Web of Science ®Google Scholar
• Piatyszek MA, Kim NW, Weinrich SL, et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 1995;17:1–15.
   Google Scholar
• Brown T, Aldous W, Lance R, et al. The association between telomerase, p53, and clinical staging in colorectal cancer. Am J Surg. 1998;175:364–366.
   PubMed Web of Science ®Google Scholar
• Garcia-Aranda C, De Juan C, Diaz-Lopez A, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer. 2006;106:541–551.
   PubMed Web of Science ®Google Scholar
• Roig AI, Wright WE, Shay JW. Is telomerase a novel target for metastatic colon cancer? Curr Colorectal Cancer Rep. 2009;5:203.
   Google Scholar
• Engelhardt M, Drullinsky P, Guillem J, et al. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3:1931–1941.
   PubMed Web of Science ®Google Scholar
• Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1807–1814.
   PubMed Web of Science ®Google Scholar
• Valls C, Piñol C, Reñé JM, et al. Telomere length is a prognostic factor for overall survival in colorectal cancer. Colorectal Dis Off J Assoc Coloproctology G B Irel. 2011;13:1265–1272.
   PubMed Web of Science ®Google Scholar
• Zackular JP, Rogers MAM, Ruffin MT, et al. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res Phila Pa. 2014;7:1112–1121.
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–78.
   PubMed Web of Science ®Google Scholar
• Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–1268.
   PubMed Web of Science ®Google Scholar
• Wong SH, Kwong TNY, Chow T-C, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2016. doi:10.1136/gutjnl-2016-312766.
   Google Scholar
• Shimada Y, Yagi R, Kameyama H, et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Hum Pathol. 2017. doi:10.1016/j.humpath.2017.02.004.
   PubMedGoogle Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–746.
   PubMed Web of Science ®Google Scholar
• Yakirevich E, Resnick MB, Mangray S, et al. Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clin Cancer Res. 2016;22:3831–3840.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023.
   PubMed Web of Science ®Google Scholar
• Tsang H-F, Xue VW, Koh S-P, et al. NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics. Expert Rev Mol Diagn. 2017;17:95–103.
   PubMed Web of Science ®Google Scholar
• Dickinson BT, Kisiel J, Ahlquist DA, et al. Molecular markers for colorectal cancer screening. Gut. 2015;64:1485–1494.
   PubMed Web of Science ®Google Scholar
• Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102–105.
   PubMed Web of Science ®Google Scholar